Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
OwnerLeif G. Salford, Bertil Persson +2inventors
InventorsLeif G. Salford, Bertil Persson, Hans Olov Sjögren, Bengt Widegren
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of 1-(β-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3-dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.
Claims32
Use of 1-(β-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one, analogue, derivative or mimetic or salts thereof for the manufacturing of a medicament for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the treatment induces indolamine dioxygenase.
Compound 1-(β-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one, analogue, derivative or mimetic or salts thereof for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the treatment induces indolamine dioxygenase.
Dependencies are inferred from the claim text.